Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M, Teulé À, Llort G, Herrero A, Sánchez-Henarejos P, Vallmajó A, González-Santiago S, Chirivella I, Cano JM, Graña B, Simonetti S, Díaz de Corcuera I, Ramon Y Cajal T, Sanz J, Serrano S, Otero A, Churruca C, Sánchez-Heras AB, Servitja S, Guillén-Ponce C, Brunet J, Denkert C, Serra V, Balmaña J. Torres-Esquius S, et al. Among authors: cano jm. JAMA Netw Open. 2024 Apr 1;7(4):e247811. doi: 10.1001/jamanetworkopen.2024.7811. JAMA Netw Open. 2024. PMID: 38648056 Free PMC article.
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Plazas JG, Arias-Martinez A, Lecumberri A, Martínez de Castro E, Custodio A, Cano JM, Hernandez R, Montes AF, Macias I, Pieras-Lopez A, Diez M, Visa L, Tocino RV, Lago NM, Limón ML, Gil M, Pimentel P, Mangas M, Granja M, Carnicero AM, Pérez CH, Gonzalez LG, Jimenez-Fonseca P, Carmona-Bayonas A. Plazas JG, et al. Among authors: cano jm. ESMO Open. 2022 Jun;7(3):100514. doi: 10.1016/j.esmoop.2022.100514. Epub 2022 Jun 14. ESMO Open. 2022. PMID: 35714478 Free PMC article.
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML, Plazas JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez Palomo A, Mangas M, Macías Declara I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez Bayona R, Pimentel P, Limón ML, Cerdá P, Álvarez Llosa R, Serrano R, Lobera MPF, Alsina M, Hurtado Nuño A, Gómez-Martin C. Jiménez-Fonseca P, et al. Among authors: cano jm. Gastric Cancer. 2017 May;20(3):465-474. doi: 10.1007/s10120-016-0639-8. Epub 2016 Sep 6. Gastric Cancer. 2017. PMID: 27599830 Free article.
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, Martín Carnicero A, Mangas M, Martín Richard M, Granja M, Ramchandani A, Hernández Pérez C, Cerdá P, Gil-Negrete A, Calvo M, Vidal Tocino R, Gallego J. Jimenez-Fonseca P, et al. Among authors: cano jm. Gastric Cancer. 2021 Mar;24(2):445-456. doi: 10.1007/s10120-020-01116-x. Epub 2020 Sep 24. Gastric Cancer. 2021. PMID: 32970266 Free PMC article.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macía-Rivas L, Arrazubi V, Cacho Lavin D, Hernandez San Gil R, Custodio A, Cano JM, Fernández Montes A, Mirallas O, Macias Declara I, Vidal Tocino R, Visa L, Limón ML, Pimentel P, Martínez Lago N, Sauri T, Martín Richard M, Mangas M, Gil Raga M, Calvo A, Reguera P, Granja M, Martín Carnicero A, Hernández Pérez C, Cerdá P, Gomez Gonzalez L, Garcia Navalon F, Pacheco Barcia V, Gutierrez Abad D, Ruiz Martín M, Weaver J, Mansoor W, Gallego J. Jimenez-Fonseca P, et al. Among authors: cano jm. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157641. doi: 10.1177/17588359231157641. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895850 Free PMC article.
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Alvarez-Manceñido F, et al. Among authors: cano jm. Gastric Cancer. 2021 Jul;24(4):926-936. doi: 10.1007/s10120-021-01169-6. Epub 2021 Mar 2. Gastric Cancer. 2021. PMID: 33651195
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J; AGAMENON study group. Carmona-Bayonas A, et al. Among authors: cano jm. Gastric Cancer. 2018 Jan;21(1):96-105. doi: 10.1007/s10120-017-0718-5. Epub 2017 Apr 9. Gastric Cancer. 2018. PMID: 28393278 Free article.
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limón ML, Granja M, Gil M, Pimentel P, Macia-Rivas L, Pérez CH, Mangas M, Carnicero AM, Cerdà P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona-Bayonas A. Valcarcel S, et al. Among authors: cano jm. J Cancer Res Clin Oncol. 2023 Jul;149(7):4077-4089. doi: 10.1007/s00432-022-04294-6. Epub 2022 Aug 30. J Cancer Res Clin Oncol. 2023. PMID: 36042046
Uncertainty and hope in relation to anxiety and depression in advanced lung cancer.
Cruz-Castellanos P, Gil-Raga M, Jiménez-Fonseca P, Ghanem I, Hernández R, Piera-Molons N, Cano JM, Gallego-Martinez A, Garcia-Torralba E, Calderon C. Cruz-Castellanos P, et al. Among authors: cano jm. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e847-e850. doi: 10.1136/spcare-2022-003882. BMJ Support Palliat Care. 2024. PMID: 36100428
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Pérez-Wert P, Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Lecumberri A, Cacho Lavin D, Losantos García I, Fernández Montes A, Cano JM, Limón ML, Hernández San Gil R, Diez M, Vidal Tocino R, Macías Declara I, Visa L, Pimentel Cáceres P, Gil Raga M, Martínez Moreno E, Sauri T, Martín Richard M, Granja M, Cerdà P, Gómez González L, Mérida-García A, Ruiz Martín M, Gallego J; AGAMENON-SEOM study group. Pérez-Wert P, et al. Among authors: cano jm. Gastric Cancer. 2024 Jan;27(1):131-145. doi: 10.1007/s10120-023-01443-9. Epub 2023 Nov 15. Gastric Cancer. 2024. PMID: 37964032
89 results